Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent update, Eli Lilly and Company, in collaboration with Tango Therapeutics, is advancing a Phase 1/2 clinical study titled Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of TNG456, a selective PRMT5 inhibitor, both as a monotherapy and in combination with Abemaciclib, a kinase inhibitor, in patients with advanced solid tumors exhibiting MTAP loss.
The intervention involves administering TNG456 alone and alongside Abemaciclib to assess its efficacy in treating solid tumors with MTAP loss. The study is structured in two phases: an initial dose escalation followed by a dose expansion across various tumor types.
The study is non-randomized and sequential, focusing on treatment as its primary purpose. It began on March 24, 2025, with its latest update on July 25, 2025, indicating active recruitment and ongoing progress.
This study could significantly impact Eli Lilly’s market position, potentially boosting investor confidence and stock performance by expanding its oncology portfolio. As the study progresses, it may also influence competitive dynamics within the pharmaceutical industry.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.